NL-OMON25042已完成不适用
A randomized phase II study investigating the addition of the specific cox-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC-IV epithelial ovarian fallopian tube or primary peritoneal carcinomas.
VU medical center0 个研究点目标入组 200 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Histologically confirmed epithelial ovarian carcinoma, fallopian tube cancer or primary peritoneal cancer;
- •2. Age ¡Ý 18 year;
排除标准
- •1. ECOG performance status > 2.
- •2. Prior treatment with chemotherapy or radiotherapy.
研究者
相似试验
已完成
不适用
A randomized phase II study investigating the addition of the specific cox-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC-IV epithelial ovarian fallopian tube or primary peritoneal carcinomasCancerISRCTN30851756VU University Medical Center (The Netherlands)200
进行中（未招募）
不适用
A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer - GeparSixtopatients with triple-negative breast cancer, patients with HER2-positive early breast cancerMedDRA version: 14.1Level: LLTClassification code 10021976Term: Inflammatory breast cancer stage IVSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10063104Term: Tubular breast cancer stage IISystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10022882Term: Invasive ductal breast cancerSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10028061Term: Mucinous breast cancer stage IISystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10006188Term: Breast cancer female NOSSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10063105Term: Tubular breast cancer stage IIISystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10021974Term: Inflammatory breast cancerSystem Organ Class: 100000004864EUCTR2011-000553-23-DEGerman Breast Group GBG Forschungsgesellschaft mbH (Sponsor nach GCP)
已完成
不适用
Effect of Celecoxib on reponse, progression-free and overall survival, when added to standaard first line chemotherapy in advanced ovarian cancer.chemotherapycelecoxibdocetaxelcarboplatinCox-inhibitorfallopian tubeprimary peritoneal cancerFIGO stage 2-4cytoreductive surgeryOvarian CancerNL-OMON23637Sanofi-AventisPfizer200
进行中（未招募）
1 期
A randomized phase II study to investigate the addition of PD-L1 antibody MEDI4736 to a taxane-anthracycline containing chemotherapy in triple negative breast cancer.(GeparNuevo)MedDRA version: 20.1Level: LLTClassification code 10071115Term: Node-negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Patients with triple negative, early breast cancerMedDRA version: 20.0Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10006200Term: Breast cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10006202Term: Breast cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10006201Term: Breast cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10071113Term: Node-positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10006199Term: Breast cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-002714-72-DEGBG Forschungs GmbH174
已完成
不适用
An ancillary study of (a randomized phase 2 study of TS-1 versus CDDP+VNR for adjuvant therapy in patients with non-small cell lung cancer)-exploratory study of cost-effectivenesson-small-cell lung cancerJPRN-UMIN000042698Clinical Research Support Center Kyushu110